Pfizer's weight loss pill trials had significant side effects

Pfizer's weight loss pill, danuglipron, caused significant side effects in trials, leading to a 4% drop in pre-market trading. The pill showed high rates of gastrointestinal side effects, with up to 73% experiencing nausea and 47% vomiting. Pfizer will focus on developing a once-daily pill. Novo Nordisk and Eli Lilly dominate the market, estimated to be worth up to $140bn. Other companies, including AstraZeneca, are eager to enter the market.